EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Progression-Free Survival of Daratumumab Versus Bortezomib Triplet Combination With Lenalidomide and Dexamethasone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma: TAURUS Chart Review Study

Lucio Navarro Gordan, Carlyn Rose Tan, Robert Vescio, Jing Christine Ye, Carolina Schinke, Rohan Medhekar, Alex Z Fu, Marie-Hélène Lafeuille, Philippe Thompson-Leduc, Vipin Khare, John Reitan, Gary Milkovich und 3 weitere

Clinical Lymphoma Myeloma and Leukemia · 2024

DOI: 10.1016/j.clml.2023.09.003 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2024. Verfasst von Lucio Navarro Gordan und 14 weiteren Autor:innen. Beteiligte Einrichtung: Florida Cancer Specialists & Research Institute, Gainesville, FL, USA. Electronic address: lgordan@flcancer.com. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Multiple Myeloma. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Janssen Pharmaceuticals, Janssen Scientific Affairs LLC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalMultiple MyelomaHumansAntineoplastic Combined Chemotherapy ProtocolsBortezomibDexamethasoneDisease ProgressionLenalidomideProgression-Free SurvivalAgedClinical Trials as Topic

Stichwörter der Autor:innen

AntibodiesDrug TherapyHematologyMonoclonalProgression-Free Survival

Substanzen

Antibodies, MonoclonalBortezomibdaratumumabDexamethasoneLenalidomide

Autor:innen und Institutionen

  • Florida Cancer Specialists & Research Institute, Gainesville, FL, USA. Electronic address: lgordan@flcancer.com.
  • Memorial Sloan Kettering Cancer Center, New York City, NY, USA.
  • Samuel Oschin Cancer Center, Cedars-Sinai, Los Angeles, CA, USA.
  • University of Michigan, Ann Arbor, MI, USA.
  • University of Arkansas, Fayetteville, AR, USA.
  • Janssen Scientific Affairs, LLC, Horsham, PA, USA.

Förderung

  • Janssen Pharmaceuticals
  • Janssen Scientific Affairs LLC

Zitieren

APA

Gordan, L. N., Tan, C. R., Vescio, R., Ye, J. C., Schinke, C., Medhekar, R., Fu, A. Z., Lafeuille, M. H., Thompson-Leduc, P., Khare, V., Reitan, J., Milkovich, G., Kaila, S., Davies, F., & Usmani, S. Z. (2024). Progression-Free Survival of Daratumumab Versus Bortezomib Triplet Combination With Lenalidomide and Dexamethasone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma: TAURUS Chart Review Study. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2023.09.003

Vancouver

Gordan LN, Tan CR, Vescio R, Ye JC, Schinke C, Medhekar R, et al. Progression-Free Survival of Daratumumab Versus Bortezomib Triplet Combination With Lenalidomide and Dexamethasone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma: TAURUS Chart Review Study. Clinical Lymphoma Myeloma and Leukemia. 2024. doi:10.1016/j.clml.2023.09.003

BibTeX
@article{Gordan2024,
  author = {Gordan, Lucio Navarro and Tan, Carlyn Rose and Vescio, Robert and Ye, Jing Christine and Schinke, Carolina and Medhekar, Rohan and Fu, Alex Z and Lafeuille, Marie-Hélène and Thompson-Leduc, Philippe and Khare, Vipin and Reitan, John and Milkovich, Gary and Kaila, Shuchita and Davies, Faith and Usmani, Saad Z},
  title = {Progression-Free Survival of Daratumumab Versus Bortezomib Triplet Combination With Lenalidomide and Dexamethasone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma: TAURUS Chart Review Study},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2024},
  doi = {10.1016/j.clml.2023.09.003}
}
Kostenlos starten →